Text Size

Role of ST2 in Acute Pancreatitis

This study has been completed.
Sponsor:
Information provided by:
Erasme University Hospital
ClinicalTrials.gov Identifier:
NCT01315613
First received: March 11, 2011
Last updated: March 14, 2011
Last verified: September 2008
History of Changes
  Purpose

Acute pancreatitis is characterized by an inflammatory storm which regulatory pathways are not well known. The IL-1 cytokine family is activated early during acute pancreatitis and secretion of alarmins is speculated during pancreatic necrosis. IL-33 is a member of the IL-1 family, it can act as an alarmin and its receptor, ST2, is known to sequester MyD88 which might regulate the acute pancreatitis inflammatory storm. The aim of this study is to investigate ST2 pathway in human acute pancreatitis and in murine experimental models of acute pancreatitis.


Condition
Acute Pancreatitis

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Study of ST2-IL-33 Pathway in Acute Pancreatitis

Resource links provided by NLM:

MedlinePlus related topics: Pancreatitis
U.S. FDA Resources

Further study details as provided by Erasme University Hospital:

Primary Outcome Measures:
  • Concentration of soluble ST2 in serum [ Time Frame: Within 30 days after onset of acute pancreatitis ] [ Designated as safety issue: No ]
    Concentration of soluble ST2 will be assessed in the serum of patient with an episode of acute pancreatitis, on the day of admission to the hospital as well as 24h, 48h, 7 days and 30 days later.


Enrollment: 44
Study Start Date: January 2005
Estimated Study Completion Date: September 2008
Primary Completion Date: September 2008 (Final data collection date for primary outcome measure)
Groups/Cohorts
Acute pancreatitis
Patients admitted in our institution for an episode of acute pancreatitis

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

Patients of Erasme University Hospital

Criteria

Inclusion Criteria:

  • Time to take blood sample less than 24h after the onset of symptoms of AP
  • Two of the following: typical pain, amylase and lipase concentrations more than 3x the upper normal limit, compatible modifications on imaging techniques

Exclusion Criteria:

  • Chronic pancreatitis
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01315613

Locations
Belgium
Erasme Hospital
Brussels, Belgium, 1070
Sponsors and Collaborators
Erasme University Hospital
Investigators
Principal Investigator: Romy Ouziel, MD Erasme Hospital
  More Information

No publications provided

Responsible Party: Romy Ouziel,, Erasme Hospital
ClinicalTrials.gov Identifier: NCT01315613     History of Changes
Other Study ID Numbers: RO-ST2
Study First Received: March 11, 2011
Last Updated: March 14, 2011
Health Authority: Belgium: Institutional Review Board

Additional relevant MeSH terms:
Pancreatitis
Pancreatic Diseases
Digestive System Diseases

ClinicalTrials.gov processed this record on June 18, 2013